SLC22A17 as a Radioligand Therapy Target
SLC22A17, solute carrier family 22 member 17, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SLC22A17 staining is highest in kidney cancer (100% of samples positive), glioma (100% of samples positive) and testicular cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is SLC22A17 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SLC22A17 expression in cancer
Protein expression of SLC22A17 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.75 | High | 100% |
| Glioma | 0.70 | High | 100% |
| Testicular Cancer | 0.53 | High | 100% |
| Head and Neck Cancer | 0.50 | Medium | 100% |
| Neuroendocrine Tumors | 0.50 | Medium | 100% |
| Cervical Cancer | 0.50 | Medium | 90% |
| Pancreatic Cancer | 0.47 | Medium | 100% |
| Liver Cancer | 0.47 | Medium | 100% |
| Bladder Cancer | 0.44 | Medium | 100% |
| Endometrial Cancer | 0.39 | Medium | 100% |
| Melanoma | 0.39 | Medium | 91% |
| Gastric Cancer | 0.36 | Medium | 100% |
| Colorectal Cancer | 0.33 | Medium | 100% |
| Thyroid Cancer | 0.33 | Medium | 100% |
| Prostate Cancer | 0.33 | Medium | 100% |
| Skin Cancer | 0.33 | Medium | 67% |
| Breast Cancer | 0.30 | Medium | 91% |
| Lung Cancer | 0.22 | Medium | 58% |
| Ovarian Cancer | 0.12 | Low | 36% |
| Lymphoma | 0.11 | Low | 17% |
Is SLC22A17 internalized?
Nuclens has not yet extracted internalization evidence for SLC22A17. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SLC22A17 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for SLC22A17 yet. Search ClinicalTrials.gov for SLC22A17 trials.
SLC22A17 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SLC22A17 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SLC22A17 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.24 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how SLC22A17 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.